- Annexon's Guillain Barre Syndrome (GBS) program, Tiruprebart, has shown **landmark data** with **90% of patients improving by week one**.  **[1528115_tx_380804_0]**  The company anticipates filing for EU MAA approval by **2026**  **[1528115_tx_380804_1]**  and expects to provide clarity on US FDA discussions regarding generalizability in **Fall 2025**.  **[1528115_tx_380804_2]** 
- Annexon intends to **monetize ex-US rights** for Tiruprebart and commercialize it in the US, targeting a concentrated hospital market where **two-thirds of GBS patients have commercial insurance**.  **[1528115_tx_380804_5]**  The EU market opportunity is estimated at **15,000 patients annually**.  **[1528115_tx_380804_6]** 
- The Geographic Atrophy (GA) program has completed Phase III enrollment ahead of schedule.  **[1528115_tx_380804_0]**  The FDA has fully signed off on the Phase III design, with **BCVA 15 letter loss as the gold standard endpoint** for vision preservation.  **[1528115_tx_380804_10]**  Data from this study is expected in **2026**.  **[1528115_tx_380804_6]** **[1528115_tx_380804_10]** 
- Annexon's oral C1s inhibitor, ANX1502, is currently in a Phase II proof-of-concept study, with data anticipated by the **end of 2025**.  **[1528115_tx_380804_11]** **[1528115_tx_380804_13]**  The company reports promising pharmacokinetic (PK) results and improved tolerability with the enteric-coated formulation.  **[1528115_tx_380804_11]**

Annexon (ANNX)